Back to search

Article

In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86

2023-12-14

Abstract excerpt

The current globally dominant SARS-CoV-2 variants are showing immune escape and reduced susceptibility to antiviral drugs. Therefore, agencies responsible for drug evaluation and regula-tion such as the FDA and EMA are revising their emergency authorization use of several COVID-19 neutralizing antibodies. These NAbs proved to be unlikely effective against new variants espe-cially Omicron descendants and several ph...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1bcaf8da-f17c-5cb7-a1cb-d773135314ab
DOI
10.20944/preprints202312.1049.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86DOI 10.20944/preprints202312.1049.v1
In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5, BA.2.86 and JN.1Semantic proximity
In Silico Evaluation of Ten Monoclonal Antibodies Neutralization Power of SARS-CoV-2 Variants EG.5, BA.2.86 and JN.1Semantic proximity
Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity
Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity
A novel consensus‐based computational pipeline for screening of antibody therapeutics for efficacy against SARS‐CoV‐2 variants of concern including Omicron variantSemantic proximity
Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizersSemantic proximity
Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron SubvariantsSemantic proximity
In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike ProteinSemantic proximity
A novel consensus-based computational pipeline for rapid screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including omicron variantSemantic proximity
AI-based antibody discovery platform identifies novel, diverse and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strainsSemantic proximity
Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity
Atlas of Currently-Available Human MAbs and Escape to Newly-Emerging Omicron BA.1/BA.1.1/BA.2/BA.3Semantic proximity
Select a neighboring publication to make it the new centre.